COVID-19 vaccination hesitancy amongst inflammatory bowel disease patients

Digestive and Liver Disease 2026 Open access

Read full text
Authors: Athanasios Naum, Anushka Deogaonkar, Lucas Miecho Heilbroner, Ishan Abdullah, Liza Khutsishvili, Marie L. Borum
DOI: 10.1016/j.dld.2026.01.216
Cited by: 0
References: 1

Abstract

We read with great interest the systematic review and meta-analysis by Ding et al. examining the effect of T cell-related vaccines on inflammatory bowel disease (IBD) activity and outcomes [1]. The authors provide a timely and comprehensive synthesis demonstrating that T cell-modulating vaccines do not significantly exacerbate IBD disease activity, offering important reassurance for clinicians managing patients receiving immunosuppressive therapy.

Fields of Study & Subjects

Vaccine Coverage and Hesitancy Inflammatory Bowel Disease SARS-CoV-2 and COVID-19 Research

Publication details

Journal / source
Digestive and Liver Disease
Volume
58
Issue
4
Pages
579–579
Publication date
12 February 2026
Language
EN